Mitochondria Morphology and DNA Content upon Sublethal Exposure to Beta-Amyloid1–42 Peptide by Andrea Diana et al.
Coll. Antropol. 32 (2008) Suppl. 1: 51–58
Original scientific paper
Mitochondria Morphology and DNA Content upon
Sublethal Exposure to Beta-Amyloid1–42 Peptide
Andrea Diana1, Goran [imi}2, Elena Sinforiani3, Nicola Orrù1, Giuseppina Pichiri4
and Giorgio Bono5
1 Department of Cytomorphology, University of Cagliari, Città Universitaria di Monserrato, Monserrato, Italy
2 Department of Neuroscience, Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Zagreb, Croatia
3 Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Neurologico C. Mondino, Pavia, Italy
4 Department of Sciences Applied to Biosystems, University of Cagliari, Città Universitaria di Monserrato, Monserrato, Italy
5 Department of Neuroscience, University of Insubria, Varese/IRCCS C. Mondino, Pavia, Italy
A B S T R A C T
Brains affected by Alzheimer’s disease (AD) show a large spectrum of mitochondrial alterations at both morphologi-
cal and genetic level. The causal link between amyloid beta peptides (Ab) and mitochondrial dysfunction has been estab-
lished in cellular models of AD using Ab concentrations capable of triggering massive neuronal death. However, mito-
chondrial changes related to sublethal exposure to Ab are less known. Here we show that subtoxic, 1 mM Ab1–42 exposure
does not change the mitochondrial shape of living cells, as visualized upon the uptake of the non-potentiometric fluores-
cent probe Mitotracker Green and enhanced yellow fluorescent protein (EYFP)-tagged cytochrome c oxidase expression.
Immunolocalization of oxidative adducts 8-hydroxy-2’-deoxyguanosine, 8-hydroxyguanine and 8-hydroxyguanosine de-
monstrates that one-micromolar concentration of Ab1–42 is also not sufficient to elicit dramatic qualitative changes in the
RNA/DNA oxidative products. However, in comparison with controls, semi-quantitative analysis of the overall mitochon-
drial mass by integrated fluorescence intensity reveals an ongoing down-regulation in mitochondrial biosynthesis or,
conversely, an enhanced autophagic demise of Ab treated cells. Furthermore, a significant increase of the full-length mi-
tochondrial DNA (mtDNA) from Ab-treated versus control cells is found, as measured by long range polymerase chain
reaction (PCR). Such up-regulation is accompanied by extensive fragmentation of the unamplified mtDNA, probably due
to the detrimental effect of Ab. We interpret these results as a sequence of compensatory responses induced by mtDNA
damage, which are devoted to repression of oxidative burst. In conclusion, our findings suggest that early therapeutic in-
terventions aimed at prevention of mitochondrial oxidative damage may delay AD progression and help in treating AD
patients.
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Introduction
Alzheimer’s disease (AD) is a late-onset, progressive,
age-dependent neurodegenerative disorder whose biolog-
ical hallmarks reside in the progressive formation of am-
yloid plaques and neurofibrillary tangles1,2, ultimately
leading to synaptic failure, disconnection syndrome and
neuronal cell death, which are clinically manifested by
the impairment of cognitive functions and changes in be-
havior and personality3. Advancements in molecular, cel-
lular and animal models of AD, as well as post-mortem
examination of brain neurons from AD patients, have re-
vealed that the formation of beta-amyloid (Ab) peptides
and their entrance into mitochondria are the prominent
factors in cellular changes in the AD brain because they
induce the generation of free radicals and oxidative dam-
age in AD brain4,5. Since neuronal viability is highly de-
pendent on oxidative energy metabolism6, the impaired
mitochondrial functions are having an enormous influ-
ence on AD manifestation and progression. Beta-amyloid
peptides increase the intracellular generation of reactive
oxygen species (ROS), particularly hydrogen peroxide
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(H2O2), thus making mitochondria both targets and so-
urces of oxidative stress7,8. In turn, oxygen derived mole-
cules give rise to oxidative adducts, such as 8-hydro-
xy-2’-deoxiguanosine (8OHdG)9,10, as a part of mitochon-
drial DNA (mtDNA) isolated from AD brains. Higher lev-
els of OHdG have been found at the initial stages of AD
in postmortem brain sections by means of immuno-
cytochemistry and the detection of oxidized nucleic acids
was shown to be reduced with disease progression11,12.
The pioneering paper by Suter and Richter13 identified
that fragmented mtDNA is the predominant carrier of
oxidized DNA bases and presence of 8OHdG. Other stud-
ies addressing prominent features of vulnerable neurons
in AD have revealed a significant reduction of cytoplas-
mic area covered by intact mitochondria, which is bal-
anced by up-regulating both average size and total mito-
chondrial DNA (mtDNA) in individual cells14. Moreover,
as revealed by in situ hybridization and immunocyto-
chemistry in the very same brain section, the overlap in
localization of mtDNA D5kb and 8OHdG seemed to sup-
port an intimate relationship between neuronal oxida-
tive damage and dysmorphic mitochondria. In contrast,
in most AD cases examined by de la Monte and colla-
borators15 the mean level of mtDNA was found to be sig-
nificantly lower than in the control group. These data
have been corroborated by the findings that in AD cells
mtDNA content was higher in cybrids that harbor low to
medium levels of 4977 bp-deleted mtDNA16. In addition,
oxidative stress induced by sublethal concentrations of
hydrogen peroxyde has been found to cause an increase
in mtDNA content that correlates with a larger amount
of functional mitochondria17,18. The quantitative rele-
vance of toxic inducers has been recently confirmed by
the ability of micromolar concentrations of hydrogen
peroxide to provoke true oxidative lesion of genomic
DNA19. However, experimental data on mtDNA is still
missing. Interestingly, while neurodegeneration can be
observed with very low doses of Ab, a dramatic viability
drop in non-primary neuronal cultures is induced only by
concentrations greater than 10 mM of Ab1–40, thus allow-
ing the definition of a threshold for the so-called subtoxic
level of Ab20.
Our current investigation was aimed to: 1) assess
whether sublethal doses of Ab1–42 could provoke specific
alterations to mitochondria both with regard to morpho-
logical and quantitative features and DNA content, 2) de-
termine if genetic and structural changes occur concomi-
tantly, and 3) verify if DNA oxidation at mitochondrial or
nuclear level can be triggered by low doses of Ab1–42.
Materials and Methods
Cell cultures
Neuroblastoma cell lines (clone SH-SY5Y) were grown
in Minimal Essential Medium (MEM) containing Earle’s
salt supplemented with 10% heat inactivated fetal bovine
serum (FBS), 2 mM L-glutamine, 1% non-essential amino
acids, streptomycin (100 mg/mL)/penicillin (100 U/mL)
(all reagents from Invitrogen, Gaithersburg, MD, USA)
and maintained at 37 °C in a humid atmosphere with 5%
CO2. One week after seeding when cells reached about
80% confluence, they were exposed to Ab1–42 peptide ace-
tate or chloride salt (Recombinant Peptide Technologies,
Athens, OH, USA) dissolved in ultra-pure water and pre-
viously incubated for 4 days at 37 °C (in order to ensure
formation of fibrils necessary for toxic induction). Fi-
nally, cells were treated for 24 hr with 1 mM Ab1–42 in
complete medium without FBS.
Gene transfection
Enhanced yellow fluorescent protein (EYFP)-tagged
cytochrome c oxidase subunit IV gene has been used to
target mitochondrial matrix21,22. SH-SY5Y cells were sta-
bly transfected with Lipofectamine 2000 (Invitrogen) by
selection with the antibiotic G418 (Invitrogen) and then
exposed to Ab1–42 as referred above.
Mitochondria labeling
After 24-hr Ab1–42 exposure, neural cells were washed
twice with PBS and supravitally stained with 400 nM
Mitotracker Green fluorescent marker (Molecular Pro-
bes, Eugene, OR, USA) diluted from 1 mM DMSO stock
solution. Cells were washed with medium and observed
using a Zeiss Axioskop microscope (Zeiss, Oberkocken,
Germany) equipped with differential interference con-
trast optics, planachromatic objective lenses (40/0.75
Na water immersion) and standard filters adapted for
Mitotracker (460–500 BP excitation, 505 splitter, 510–
560 BP emission). Grayscale images were acquired by a
8-bit cooled CCD camera (Sensicam, PCO Computer Op-
tics, Kehlheim, Germany) with a 12801024 pixel chip.
Image analysis was performed using the Image-Pro Plus
software (Media Cybernetics, Silver Spring, MD, USA).
Immunocytochemistry
A monoclonal mouse antibody against oxidative ad-
ducts 8-hydroxy-2’-deoxyguanosine, 8-hydroxyguanine,
and 8-hydroxyguanosine (anti-8OHdG) was used as a
marker of DNA (both genomic and mitochondrial) and
RNA oxidative damage (Autogen Bioclear, Calne, UK).
Neuroblastoma cells were fixed in periodate-lysine-para-
formaldehyde (PLP) for 15 min at 37 °C. After rinsing
with PBS containing 0.2% Triton X-100, 10% normal
goat serum (NGS) (Vector Laboratories Inc., Burlinga-
me, CA, USA) was applied for 1 hr at room temperature
(RT). Then, anti-OHdG antibody (5 mg/mL) diluted in
PBS containing 0.3% Triton X-100 and 2% NGS was
added for 24 hr at RT. After an extensive washing with
PBS, samples were incubated for 40 min at RT with
fluorescein (FITC) conjugated anti-mouse antibody (Ja-
ckson Immunoresearch Labs, West Grove, PA, USA), and
rinsed with PBS. Nuclear morphology was evaluated by
DAPI staining (5 mg/mL; Molecular Probes, Eugene, OR,
USA) for 5 min at RT. Cell imaging and analysis were
performed as described above.
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DNA extraction
Cells were scraped, centrifuged at 500x g for 10 min
and resuspended in extraction buffer composed of 10 mM
Tris-HCl (pH 8), 100 mM EDTA (pH 8), 20 mg/mL RNAse,
0.5% SDS and 0.1 mg/ml proteinase K. The samples were
then gently shaked for 18 hr at RT. DNA extraction was
carried out at 4 °C according to Blin and Stafford23, with
some modifications. First, an equal volume of phenol/
chloroform/isoamyl alcohol 25/24/1 mixture was added.
Upon centrifugation (1500x g, 10 min), the aqueous
phase was transferred to a new tube with an equal
amount of chlorophorm/isoamyl alcohol 24/1 and then
centrifuged again. DNA was precipitated by adding 0.3 M
sodium acetate, pH 5.2 (1 volume), 100% cold ethanol (2
volume), then air dried and immediately dissolved in ul-
tra-pure water.
Long extension Polymerase Chain Reaction
(LX-PCR)
Long extension PCR for amplification of the entire
mitochondrial genome was carried out using outwards
primers located in the cytochrome b gene8 that corre-
spond to the following sequences:
5’-TGAGGCCAAATATCATTCTGAGGGGC-3’
(forward primer, 15148-15174 bp) and
5’-TTTCATCATGCGGAGATGTTGGATGG-3’
(reverse primer, 14841-14816 bp), to generate a 16231 bp
molecule.
The reaction components (25 mL) consisted of 0.5 mM
dNTPs (Pharmacia, Uppsala, Sweden), 0.3 mM primers
(MWG-Biotech, Firenze, Italy), 100 ng genomic DNA as a
bottom phase. This master mix was overlaid with 25 mL
of 1x buffer and 2.5 Us enzyme mixture (Expand long
template PCR system, Roche Diagnostics GmbH, Mann-
heim, Germany). Thermo-cycling profile involved the fol-
lowing steps: 1) initial denaturation (92 °C, 2 min), 2) de-
naturation (92 °C, 10 sec), annealing (70 °C, 30 sec),
extension (68 °C, 12 min), for a total of 10 cycles, 3) dena-
turation (92 °C, 10 sec), annealing (70 °C, 30 sec) with in-
creasing annealing time by 20 sec increments in each
successive cycle, extension (68 °C, 12 min), for a total of
20 cycles, and 4) final extension (68 °C, 7 min). PCR prod-
ucts were loaded onto a 0.4% MP agarose gel (Roche Di-
agnostics GmbH, Mannheim, Germany) in 1x Tris-Ace-
tate-EDTA (TAE) at 25 V for 18 h. Finally, gel was
stained with Sybr Green (Molecular Probes, Eugene, OR,
USA) according to the manufacturer instructions.
In order to avoid possible quantitative differences due
to methodological reasons several DNA purified samples
were amplified and run on the same gel in the same elec-
trophoresis chamber.
Determination of mitochondrial mass
and statistics
All of the experiments have been repeated at least
three times. Mitochondrial mass was evaluated by mea-
suring the integrated fluorescence intensity of mitochon-
drial profiles stained by Mitotracker dye under assump-
tion that dye is insensitive to differences in potential.
Due to the considerable skewness of distributions, data
comparisons were made using the non-parametric test of
Kruskal-Wallis with a significance level of p<0.05.
Results
Although Ab-treated cells were having higher levels of
oxidative damage (see below), both control (Figure 1a)
and Ab-treated cells (Figure 1b) showed bright immuno-
fluorescence for 8OhdG and appeared relatively similar.
As to the cytological distribution of oxidative adducts,
again in both Ab-treated and control cells 8OHdG was
mainly concentrated in the cytoplasmic domain with
peaks of fluorescence in the perinuclear area, whereas
nuclei showed a very weak immunolabeling. In addition,
the largest cells displayed a granular immunolocalization
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Fig. 1. Distribution of anti-8OHdG immunofluorescence. a: Un-
der basal conditions, 8OHdG-like immunolabeling is strongly de-
tected in the cytoplasmic domain while nuclei reveal very low
immunoreactivity. Notably, the largest cells contain a granular
fluorescent signal spread over the abundant cytoplasm. Some neu-
rites are also stained by the anti-8OHdG antibody. b: Cells exposed
to Ab1–42 are also immunopositive regardless to the cell size. Scale
bar = 10 mM.
regardless of Ab exposure, probably as a consequence of
the segregation of oxidative DNA/RNA adducts within
organelles (e.g. ribosomes and mitochondria). Fluores-
cent traces were also present along the emergence of
neuronal processes that soon disappeared at longer dis-
tance.
Morphological analysis was based on mitochondrial
staining by Mitotracker uptake and EYFP cytochrome c
oxidase transfected cells. Mitochondria of control cells la-
beled with Mitotracker were highly fluorescent. Fluores-
cence was distributed throughout the cytoplasm appar-
ently in conjunction with a reticular organization of fila-
mentous profiles (Figure 2a). However, despite the conti-
nuity of mitochondrial network, Mitotracker load was
often variable from cell to cell. Due to the inherent prop-
erties of Mitotracker used, this phenomenon could not be
ascribed to fluctuations of mitochondrial potential. Un-
even distribution of the dye was quite similar to the one
observed in mitochondria of Ab treated samples (Figure
2b). We therefore measured the integrated area of sev-
eral fluorescent mitochondria. In comparison to controls
(7664, 9275.9, 8036.2), we found a significant decrease in
median values of the randomly selected and examined Ab
samples (7368.7, 4812.6, 7462.55, respectively). Alter-
ations of mitochondrial network were absent in Ab ex-
posed cells, as confirmed by incubation with an excess of
phosphate salts that triggered a robust swelling accom-
panied by extensive fragmentation of mitochondria (Fig-
ure 2c).
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Fig. 2. Mitochondria distribution and shape upon Mitotracker
uptake. a: Control cells display a reticular organization of mito-
chondria filling the whole cytoplasm, but rarely reaching the neu-
ritic processes. The highest peaks of fluorescence are obtained pos-
sibly due to overlapping of mitochondrial elements. b: In Ab1-42
treated cells, the overall architecture of mitochondria was unal-
tered as compared to control cells, albeit with the additional fea-
ture of isolated cells being more sensitive to photobleaching. c:
Incubation of neuroblastoma cells in hypotonic solution affects
the continuity and size of fluorescent mitochondria. As a result,
fragmented and swollen structures can be observed. Scale bar =
10 mM.
Fig. 3. EYFP-tagged cytochrome c oxidase protein expression in
living cells. a: The distribution pattern in control cells is consis-
tent with the specific accumulation within the mitochondria. Mi-
tochondria are represented by a mesh of filaments sometimes de-
tectable in the shape of single string. b: Ab1–42 has no effect on
EYFP labeled mitochondria. The fluorescent dots could be occas-
sionally detected, probably due to the initial storage of the cyto-
chrome c oxidase. Scale bar = 10 mM.
By means of transfection, in neuronal cells containing
mitochondria tagged with EYFP, the import of the cyto-
chrome oxidase subunit IV into the mitochondrial matrix
resulted in a specific mitochondrial morphology. Our
data showed a fluorescent pattern overlapping with Mi-
totracker stained mitochondria (Figure 3a). In addition,
mitochondria filaments extended their localization to
neuritic processes. The exposure to 1mM Ab seemed to be
ineffective at inducing mitochondria to become frag-
mented or swollen (Figure 3b). Observed enlargements
could be occasionally distinguished along mitochondrial
strings, but were independent to the Ab treatment.
Results of LX-PCR experiments showed the single
distinct band corresponding to ~16.3 kb of the entire mi-
tochondrial human genome (Figure 4). Interestingly, the
sharp band (16.3 kb) obtained with the two Ab samples
was roughly double in thickness compared to the corre-
spondent mtDNA of control cells. In addition, PCR prod-
ucts from Ab treated cells consisted of a smear of frag-
ments with higher and lower average length plus two
more fragments with very low molecular weight. Such
findings were not replicated with amplified DNA from
control cells. Moreover, electrophoresis of mtDNA sho-
wed a higher background which was representative of
random DNA fragmentation when the neuroblastoma
cells had been cultured in presence of the toxic peptides.
Discussion
During last several years the relationship between
mitochondria dysfunctions and Ab accumulation have
gained increasing interest due to pivotal role of mito-
chondria in the AD neurodegenerative process25–27. Within
this framework, one of the major issues is an unpredict-
able time window between Ab driven plaque formation
and the occurrence of clinical symptoms of AD. In search
of initial signals affecting mitochondrial architecture and
mtDNA content, we designed an experimental model
where low dose exposure to Ab1–42 was well below the
threshold for inducing immediate cell death, but still
high enough for the induction of subtle cellular changes.
The main finding of this study is that total mtDNA
content was up-regulated in Ab treated cells compared to
control cells, as revealed by LX-PCR. The extensive in-
crease of mtDNA was also accompanied by a higher de-
gree of fragmentation, as visualized by a more evident
smear of DNA and thicker bands of DNA with low molec-
ular weights. These findings indicate that DNA synthesis
may occur concomitantly with a diffuse degradation of
mitochondrial genome. This is consistent with previous
reports where the increase of mtDNA and mitochondria
has been interpreted as one of the molecular events gear-
ing the cells up to cope with mild to medium stress17,18.
However, when cells are overwhelmed by high oxidative
stress, due to the impaired replication of mtDNA and
biogenesis of mitochondria, such a physiological switch
may be no longer be effective.
A measurement of total mtDNA in a pure population
of neuronal cells has not been extensively studied. The
only two papers14,15 that have systematically addressed
the variability of mtDNA content in postmortem AD
brains ended up with conclusions that are difficult to re-
solve. The first group reported a reduction of mtDNA in
AD that positively correlated with an increase in mtDNA
fragmentation, but was »paradoxically« linked to the in-
crease of mitochondrial mass14. On the other hand, al-
though total mtDNA in AD was increased in several
neuronal populations, much of this mtDNA was present
in digestive organelles and therefore potentially unsuit-
able for extraction and amplification, as observed by the
other group15. Due to the reduced numbers of intact mi-
tochondria the amount of amplifiable mtDNA was also
reduced15. We think that those divergent and controver-
sial results might be explained on the basis of different
methodological approaches. Namely, at least some of the
differences obtained could be attributed to excessive glial
cell reaction associated with cell loss or proliferation of
mitochondria in degenerating neurons, which could also
heighten the overall mitochondrial genetic content. In
our study, we were confident that the specificity of the
primers within the highly conserved cytochrome b gene
made the LX-PCR method qualitatively reliable for the
amplification of a linear product equivalent to the entire
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Fig. 4. SYBR Green stained gel of LX-PCR using DNAs from two
different experiments (see text for explanation). Specific bands re-
presentative of the entire mitochondrial genome (16.3 Kb) exhib-
ited the strongest signal in the Ab1–42 samples. A smear of frag-
ments above or below 16.3 Kb was more enhanced in the presence
of Ab1–42. The additional band between 10 and 8.6 Kb was more
evident in DNAs of treated cells. Duplicate experiments of control
and Ab1–42 DNAs were indicated as C1, C2 and Ab1, Ab2 respec-
tively.
mitochondrial genome24, what allows the detection of
mutational events such as deletions in different tissu-
es28,29, including the human brain30. However, this me-
thod has also received a lot of criticism as a quantitative
assay due to possible technical artifacts (e.g. variations in
template DNA concentration) that can lead to the misin-
terpretation of LX-PCR results31. The only alternative
source of information that may help resolving this puzzle
has been offered through the analysis of AD brain tissues
where much of the increased mtDNA was ultrastruc-
turally segregated in autophagocytic compartments and
therefore unavailable for PCR amplification14.
We also tried to verify a positive correlation between
the quantitative variation of the mitochondrial genome
and possible alterations in terms of mass and shape of
the overall mitochondria. Measurements of integrated
fluorescence area for the evaluation of total mitochon-
drial mass revealed a slight, though statistically signifi-
cant, decrease of the overall content of mitochondria in
case of Ab exposure. This finding is consistent with the
absence of clear morphological alterations of mitochon-
dria such as swelling or fragmentation. Indeed, without
any de novo mitochondria biosynthesis, only enlarge-
ments of mitochondria could eventually account for a to-
tal increase in the TMRM (tetramethyl rhodamine me-
thyl ester) stained fluorescent area. Despite the fact that
the morphology and dynamics mitochondria have tissue
and cell specific features32, in vivo image analysis has
shown a direct correlation between mitochondrial DNA
depletion and disruption of the mitochondrial reticulum,
which resulted in formation of vesicular organelles with
circular cristae33. A confirmation of this phenomenon
has emerged from description of individual mitochondria
changing their morphology in accordance with mtDNA
redistribution and intimate relationship to cell cycle pha-
ses34.
Some previous reports have shown that, in compari-
son to controls, an approximately eightfold increase in
morphologically abnormal (swelled or enlarged) mito-
chondria after six passages of cybrid cell lines from spo-
radic AD subjects35. In contrast to these reports, we have
demonstrated that up-regulation of the mitochondrial
genome does not necessarily imply either such a great in-
crease of mitochondrial mass or an impairment of nor-
mal morphology. This result is relevant since it is sup-
posed that low levels of Ab would have mtDNA as a
primary target before the appearance of the irreversible
damage of mitochondrial filaments. At this point it should
be clarified that in our model we circumvented possible
unspecificity of TMRM due to inefficient uptake or the
ongoing efflux mediated by MDR pumps upon Ab treat-
ment by using EYFP cytochrome c oxidase transfected
cells. This method has been extensively used to track mi-
tochondria because of the transmembrane distribution of
the enzyme. Cytochrome c oxidase-tagged mitochondria
were also resistant to the toxic effects of Ab because the
continuity of fluorescence pattern was unchanged even
after the amyloid insult. This finding confirmed earlier
notion that in physiological conditions the reticular form
better drives rapid transmission of energy through the
propagation of a membrane potential and therefore facil-
itates energy delivery from the cell periphery to the cell
core36.
Finally, since a recent review37 proposed a »chame-
leon« role for Ab (a phenomenon obviously dependent
upon Ab concentration which, in turn, determines in vi-
tro fibrillization rate), always swinging between the pro-
oxidant and anti-oxidant activities, in this study we also
investigated if Ab1–42 exposure is per se a biochemical in-
ducer of DNA oxidation. Although some previous reports
found 8OHdG-immunopositive neurons in AD brain sec-
tions12, we have found no experimental evidence in neu-
ronal cell culture to support this view. Since in our model
we observed a steady-state level of 8OHdG immuno-
reactivity, our results are consistent with the antioxidant
role of Ab1–42 when applied at concentrations lower than
10 mM. These data were also validated by the minimal
fraction of cells that were committed to cell death (data
not shown), and are in accordance with the published ob-
servations where 5 mM Ab induced only 15% decrease in
the viability properties of SY5Y cells, as compared to
controls38.
Recent advances in model studies of AD have revealed
that Ab and other amyloid precursor protein (APP) de-
rivatives (particularly mutated ones) are key factors which
enter into mitochondria and induce the generation of
free radicals and oxidative damage in AD neurons5. Evi-
dence from biochemical and gene expression studies has
also suggested that mitochondrial abnormalities per se
are critical for the initiation of late-onset sporadic AD4.
However, the precise causal links between mitochondrial
abnormalities and synaptic damage-based cognitive de-
cline are still unknown. Since currently approved drugs
for AD (acetylcholinesterase inhibitors tacrine, galanta-
mine, donepezil and rivastigmine and non-competitive
antagonist of NMDA receptors memantine) provide only
temporary relief of some symptoms of dementia and do
not modify AD pathology, there is an urgent need for de-
velopment of alternative therapeutic strategies. Antioxi-
dants tested so far were found to be safe, had few adverse
effects, readily crossed blood brain barrier and appear to
be a promising mitochondrial medicine to improve cogni-
tive functions of AD patients5. In this context, the results
reported here may serve as a starting point for develop-
ment of more sophisticated models of beta amyloid toxic-
ity in which the action of anti-oxidative compounds could
be tested. On the other side, it would be of particular rel-
evance to test how modulation of metal ions (such as cop-
per, zinc and iron) reduction affect mitochondrial DNA
oxidation in the presence of minimal amounts of fibri-
llogenic Ab.
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MORFOLOGIJA I STANJE DNA MITOHONDRIJA NAKON SUBLETALNE EKSPOZICIJE
PEPTIDOM BETA-AMILOIDA1–42
S A @ E T A K
U mozgova osoba s Alzheimerovom bole{}u (AD) vidi se veliki spektar mitohondrijalnih promjena kako na morfolo-
{koj, tako i na genetskoj razini. U stani~nim modelima AD prona|ena je kauzalna povezanost izme|u prisutnosti pepti-
da beta-amiloida (Ab) i disfunkcije mitohondrija samo uz upotrebu koncentracija Ab koje su sposobne izazvati masivnu
smrt neurona. No, mitohondrijalne promjene povezane sa subletalnom ekspozicijom Ab nisu tako dobro prou~ene. U
ovom smo istra`ivanju pokazali da subtoksi~na ekspozicija s 1 mM Ab1–42 ne mijenja oblik mitohondrija stanica u kul-
turi, {to je jasno vidljivo nakon vizualizacije mitohondrija pomo}u na razlike u potencijalu neosjetljive fluorescentne
probe Mitotracker Green i na temelju ekspresije citokrom c oksidaze ozna~ene modificiranim `utim fluorescentnim
proteinom s pobolj{anom emisijom (EYFP). Imunolokalizacija oksidativnih kompleksa 8-hidroksi-2’-deoksigvanozina,
8-hidroksigvanina i 8-hidroksigvanozina pokazala je da jednomolarna koncentracija Ab1–42 tako|er nije dovoljna da bi
izazvala dramati~ne kvalitativne promjene vizualiziranih oksidativnih produkata RNA i/ili DNA. Ipak, u usporedbi s
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kontrolama, semikvantitativnom analizom mitohondrijalne mase izmjerene iz intenziteta ukupne fluorescencije otkrili
smo zna~ajne razlike koje ukazuju da dolazi ili do sveukupnog smanjivanja biosinteze mitohondrija ili pak da se radi o
poja~anoj autofagi~koj eliminaciji stanica tretiranih s Ab. Nadalje, upotrebom lan~ane reakcije polimeraze dugog odsje-
~ka (long range PCR) u stanica tretiranih s Ab prona{li smo zna~ajan porast cijele mitohondrijalne DNA (mtDNA).
Ovakva poja~ana sinteze cijele mtDNA bila je popra}ena izra`enom fragmentacijom neamplificirane mtDNA, vjero-
jatno uslijed {tetnog djelovanja Ab. Dobivene rezultate interpretirali smo kao niz kompenzatornih procesa izazvanih
o{te}enjem mtDNA, kojima je cilj zaustavljanje naglog porasta oksidacije. Zaklju~no, na{i nalazi ukazuju da bi rane
terapijske intervencije usmjerene na prevenciju oksidativnog o{te}enja mitohondrija mogle odgoditi progresiju AD i
pomo}i u lije~enju bolesnika s AD.
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